Important new treatment for the most common skin cancer (basal cell carcinoma) called Erivedge (vismodegib)
The FDA approved a novel new treatment for the most common kind of skin cancer. The drug is called Erivedge (vismodegib) and treats patients with basal cell carcinoma.
A medicine which first received notariety at the American Society of Clinical Oncologists (ASCO) this summer was approved by the FDA today. This drug is the first in a new family of medicines called anti-CTLA 4 inhibitors.
Activatng the immune system is a relatively new model for attacking cancer, but it appears to be coming of age. While "true breakthrough" is a term rarely applied in most treatments, ipilimumab (proposed brand-Yervoy) may be just that for patients with melanoma.